Acquisition by Yerxa Benjamin R of 10000 shares of Opus Genetics, at 0.9834 subject to Rule 16b-3

Read at macroaxis.com

Published over a month ago View all stories for Opus Genetics, | Opus Genetics, Hype Analysis

Acquisition of 10000 common stock at 0.9834 of Opus Genetics, by Yerxa Benjamin R on 21st of November 2024. This event was filed by Opus Genetics, with SEC on 2024-11-21. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Opus Genetics,'s cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Opus Genetics,'s relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.

We analyze Opus Genetics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Opus Genetics, stock to make a market-neutral strategy. Peer analysis of Opus Genetics, could also be used in its relative valuation, which is a method of valuing Opus Genetics, by comparing valuation metrics with similar companies.

When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.